PFE

SEC source: 0001225208-25-003917 · doc4.xml · derivative · entry 1

Quincey James · CIK 0001561264 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,443.047

Underlying: Common Stock · 1,529.203 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.

F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.

SEC source: 0001225208-25-003918 · doc4.xml · derivative · entry 1

SMITH JAMES C · CIK 0001611777 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 143,564.319

Underlying: Common Stock · 1,775.848 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.

F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.

SEC source: 0001225208-25-003919 · doc4.xml · derivative · entry 1

Taraporevala Cyrus · CIK 0001454920 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,709.697

Underlying: Common Stock · 1,479.874 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.

F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.

SEC source: 0001225208-25-003451 · doc4.xml · derivative · entry 1

BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 705,449

Underlying: Common Stock · 1,905 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0001225208-25-003063 · doc4.xml · derivative · entry 1

BOSHOFF CHRISTOFFEL · CIK 0001988687 · President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 495,765

Underlying: Common Stock · 495,765 shares

Expires 2030-03-04

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-25-003064 · doc4.xml · derivative · entry 1

BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,487,296

Underlying: Common Stock · 1,487,296 shares

Expires 2030-03-04

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-25-003067 · doc4.xml · derivative · entry 1

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,992

Underlying: Common Stock · 156,992 shares

Expires 2030-03-04

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-25-003068 · doc4.xml · derivative · entry 1

LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 371,824

Underlying: Common Stock · 371,824 shares

Expires 2030-03-04

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-25-003070 · doc4.xml · derivative · entry 1

McDermott Michael · CIK 0001902464 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 289,196

Underlying: Common Stock · 289,196 shares

Expires 2030-03-04

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-25-003071 · doc4.xml · derivative · entry 1

SAHNI PAYAL · CIK 0001817124 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 206,569

Underlying: Common Stock · 206,569 shares

Expires 2030-03-04

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-25-003072 · doc4.xml · derivative · entry 1

SUSMAN SALLY · CIK 0001263544 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,992

Underlying: Common Stock · 156,992 shares

Expires 2030-03-04

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-25-003073 · doc4.xml · derivative · entry 4

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,511

Underlying: Common Stock · 47,511 shares

Expires 2030-03-04

F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-25-003073 · doc4.xml · nonDerivative · entry 3

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,850

SEC source: 0001225208-25-003073 · doc4.xml · nonDerivative · entry 2

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,350

F2 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements.

SEC source: 0001225208-25-003074 · doc4.xml · derivative · entry 1

de Germay Alexandre · CIK 0002005574 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 371,824

Underlying: Common Stock · 371,824 shares

Expires 2030-03-04

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-25-003075 · doc4.xml · derivative · entry 1

MALIK AAMIR · CIK 0001881510 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 371,824

Underlying: Common Stock · 371,824 shares

Expires 2030-03-04

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-25-003076 · doc4.xml · derivative · entry 1

Denton David M · CIK 0001428718 · Chief Financial Officer & EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 413,138

Underlying: Common Stock · 413,138 shares

Expires 2030-03-04

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-25-003077 · doc4.xml · derivative · entry 1

Baum Andrew · CIK 0002029853 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 206,569

Underlying: Common Stock · 206,569 shares

Expires 2030-03-04

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-25-002703 · doc4.xml · derivative · entry 5

BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 582,823 shares

Expires 2025-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-25-002703 · doc4.xml · nonDerivative · entry 3

BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 367,589

F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

SEC source: 0001225208-25-002703 · doc4.xml · nonDerivative · entry 2

BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 913,444

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

SEC source: 0001225208-25-002703 · doc4.xml · nonDerivative · entry 1

BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 931,744

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001225208-25-002704 · doc4.xml · derivative · entry 4

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 72,629 shares

Expires 2025-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-25-002704 · doc4.xml · nonDerivative · entry 3

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,829

F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

SEC source: 0001225208-25-002704 · doc4.xml · nonDerivative · entry 2

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,851

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

SEC source: 0001225208-25-002704 · doc4.xml · nonDerivative · entry 1

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,534

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001225208-25-002705 · doc4.xml · derivative · entry 5

LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 156,914 shares

Expires 2025-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-25-002705 · doc4.xml · nonDerivative · entry 3

LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 159,240

F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

SEC source: 0001225208-25-002705 · doc4.xml · nonDerivative · entry 2

LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 306,201

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

SEC source: 0001225208-25-002705 · doc4.xml · nonDerivative · entry 1

LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 309,790

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001225208-25-002706 · doc4.xml · derivative · entry 4

McDermott Michael · CIK 0001902464 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 48,419 shares

Expires 2025-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-25-002706 · doc4.xml · nonDerivative · entry 3

McDermott Michael · CIK 0001902464 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,958

F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

SEC source: 0001225208-25-002706 · doc4.xml · nonDerivative · entry 2

McDermott Michael · CIK 0001902464 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,305

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

SEC source: 0001225208-25-002706 · doc4.xml · nonDerivative · entry 1

McDermott Michael · CIK 0001902464 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,413

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001225208-25-002707 · doc4.xml · derivative · entry 5

SAHNI PAYAL · CIK 0001817124 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 19,054 shares

Expires 2025-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-25-002707 · doc4.xml · nonDerivative · entry 3

SAHNI PAYAL · CIK 0001817124 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,928

F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

SEC source: 0001225208-25-002707 · doc4.xml · nonDerivative · entry 2

SAHNI PAYAL · CIK 0001817124 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,774

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

SEC source: 0001225208-25-002707 · doc4.xml · nonDerivative · entry 1

SAHNI PAYAL · CIK 0001817124 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,242

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001225208-25-002708 · doc4.xml · derivative · entry 5

SUSMAN SALLY · CIK 0001263544 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 85,182 shares

Expires 2025-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-25-002708 · doc4.xml · nonDerivative · entry 3

SUSMAN SALLY · CIK 0001263544 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 168,909

F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

SEC source: 0001225208-25-002708 · doc4.xml · nonDerivative · entry 2

SUSMAN SALLY · CIK 0001263544 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 248,688

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

SEC source: 0001225208-25-002708 · doc4.xml · nonDerivative · entry 1

SUSMAN SALLY · CIK 0001263544 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,866

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001225208-25-002709 · doc4.xml · nonDerivative · entry 2

BOSHOFF CHRISTOFFEL · CIK 0001988687 · President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 163,238

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of performance share awards (including dividend equivalents thereon).

SEC source: 0001225208-25-002709 · doc4.xml · nonDerivative · entry 1

BOSHOFF CHRISTOFFEL · CIK 0001988687 · President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 172,147

F1 · shares: The reported transaction constitutes the earn-out of performance share awards (including dividend equivalents thereon).

SEC source: 0001225208-25-002710 · doc4.xml · derivative · entry 4

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,416 shares

Expires 2025-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-25-002710 · doc4.xml · nonDerivative · entry 3

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,516

F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

SEC source: 0001225208-25-002710 · doc4.xml · nonDerivative · entry 2

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,510

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

SEC source: 0001225208-25-002710 · doc4.xml · nonDerivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,063

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001225208-25-003073 · doc4.xml · nonDerivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,761

F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

SEC source: 0001225208-25-002612 · doc4.xml · nonDerivative · entry 2

BOSHOFF CHRISTOFFEL · CIK 0001988687 · President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,100

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of performance share awards (including dividend equivalents thereon).